Porton drops listing plan and seeks merger or sale
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.PORTON International, the private biotechnology company in which institutions invested pounds 76m, is seeking a merger or sale. A stock market listing has been ruled out, writes Russell Hotten.
Profits have been disappointing since Porton was set up in 1982 - about pounds 3m on turnover of pounds 49.1m in 1992 - though business is thought to have improved.
Gordon Duncan, of Kleinwort Benson, the merchant bankers recently engaged to promote the company, said several potential purchasers or partners had made approaches.
Porton is owned by 44 institutional shareholders, including Sun Alliance and Legal and General, and Wensley Haydon-Baillie, the founder and former chairman who still has about one-third of the company. Porton makes vaccines and markets drugs for leukaemia and muscular problems.
In 1985 it forecast profits of pounds 140.6m in 1990. But it suffered from reputations for secrecy and high executive salaries.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments